(Q59122940)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Alison M Michie

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Helen Wheadon

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

O Middleton

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

E Dobbin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

A M McCaig

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

C Clarke

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

A M Brant

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

M T Leach

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

2 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

107-114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2014.146

17 March 2020

exact match

0 references

cites work

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Mice carrying a CD20 gene disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Store-operated cation entry mediated by CD20 in membrane rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Complement. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Defective complement activity in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.146

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

21 January 2018

1 reference

12 December 2020

C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance

1 reference

12 December 2020

Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia

1 reference

12 December 2020

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

12 December 2020

Depressed classical complement pathway activities in chronic lymphocytic leukaemia

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2014.146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24787488%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference